(ABCL) Abcellera Biologics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.067m USD | Total Return: 65.4% in 12m

Antibody Drugs, Drug Discovery, Clinical Trials
Total Rating 48
Safety 77
Buy Signal -0.79
Biotechnology
Industry Rotation: +3.6
Market Cap: 1.07B
Avg Turnover: 7.78M USD
ATR: 5.43%
Peers RS (IBD): 14.8
Risk 5d forecast
Volatility68.6%
Rel. Tail Risk-9.68%
Reward TTM
Sharpe Ratio0.92
Alpha36.88
Character TTM
Beta1.949
Beta Downside1.802
Drawdowns 3y
Max DD75.72%
CAGR/Max DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of ABCL over the last years for every Quarter: "2021-03": 0.37, "2021-06": -0.01, "2021-09": -0.08, "2021-12": 0.19, "2022-03": 0.54, "2022-06": -0.02, "2022-09": 0.08, "2022-12": -0.1, "2023-03": -0.14, "2023-06": -0.11, "2023-09": -0.1, "2023-12": -0.17, "2024-03": -0.14, "2024-06": -0.13, "2024-09": -0.17, "2024-12": -0.12, "2025-03": -0.15, "2025-06": -0.12, "2025-09": -0.19, "2025-12": -0.03, "2026-03": 0,
EPS CAGR: 2.82%
EPS Trend: -22.2%
Last SUE: 2.70
Qual. Beats: 2
Revenue Revenue of ABCL over the last years for every Quarter: 2021-03: 202.741, 2021-06: 27.643, 2021-09: 5.508, 2021-12: 139.331, 2022-03: 316.581, 2022-06: 45.917, 2022-09: 101.383, 2022-12: 21.545, 2023-03: 12.192, 2023-06: 10.056, 2023-09: 6.599, 2023-12: 9.179, 2024-03: 9.954, 2024-06: 7.323, 2024-09: 6.507, 2024-12: 5.05, 2025-03: 4.235, 2025-06: 17.084, 2025-09: 8.955, 2025-12: 44.854, 2026-03: null,
Rev. CAGR: -40.61%
Rev. Trend: -53.6%
Last SUE: 4.00
Qual. Beats: 1
Warnings

Interest Coverage Ratio -8.2 is critical

volatile

Tailwinds

pead

Description: ABCL Abcellera Biologics

AbCellera Biologics Inc. (ABCL) focuses on antibody drug discovery and development for unmet medical needs in the United States.

The companys pipeline includes ABCL635, a non-hormonal treatment for vasomotor symptoms in Phase 2, and ABCL575, a monoclonal antibody for autoimmune conditions like atopic dermatitis in Phase 1. Drug development is a lengthy process, often taking over a decade to bring a new medicine to market.

ABCL has established collaborations with major pharmaceutical companies, including Eli Lilly and Company and AbbVie Inc., and partnerships with investment firms and Biogen Inc.

For more detailed financial and operational data, ValueRay offers comprehensive analysis.

Headlines to Watch Out For
  • Clinical trial success for ABCL635 impacts future revenue
  • Partnership milestones with Eli Lilly drive income
  • Research collaboration revenue fluctuates with drug discovery progress
  • Regulatory approval timelines affect commercialization
  • R&D expenses influence profitability
Piotroski VR‑10 (Strict) 0.0
Net Income: -146.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.13 > 0.02 and ΔFCF/TA 0.87 > 1.0
NWC/Revenue: 883.7% < 20% (prev 2.34k%; Δ -1.46k% < -1%)
CFO/TA -0.10 > 3% & CFO -131.3m > Net Income -146.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 11.32 > 1.5 & < 3
Outstanding Shares: last quarter (298.7m) vs 12m ago 1.40% < -2%
Gross Margin: -10.41% > 18% (prev -2.36%; Δ -805.0% > 0.5%)
Asset Turnover: 5.53% > 50% (prev 2.12%; Δ 3.41% > 0%)
Interest Coverage Ratio: -8.17 > 6 (EBITDA TTM -175.3m / Interest Expense TTM 24.2m)
Altman Z'' 5.91
A: 0.49 (Total Current Assets 728.2m - Total Current Liabilities 64.3m) / Total Assets 1.36b
B: -0.02 (Retained Earnings -29.5m / Total Assets 1.36b)
C: -0.15 (EBIT TTM -197.4m / Avg Total Assets 1.36b)
D: 3.57 (Book Value of Equity 768.6m / Total Liabilities 215.6m)
Altman-Z'' Score: 5.91 = AAA
Beneish M -2.33
DSRI: 0.64 (Receivables 153.4m/92.1m, Revenue 75.1m/28.8m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.75 (AQ_t 0.15 / AQ_t-1 0.20)
SGI: 2.61 (Revenue 75.1m / 28.8m)
TATA: -0.01 (NI -146.4m - CFO -131.3m) / TA 1.36b)
Beneish M-Score: -2.33 (Cap -4..+1) = BBB
What is the price of ABCL shares? As of April 07, 2026, the stock is trading at USD 3.52 with a total of 3,490,358 shares traded.
Over the past week, the price has changed by +3.35%, over one month by -1.74%, over three months by -13.08% and over the past year by +65.37%.
Is ABCL a buy, sell or hold? Abcellera Biologics has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABCL.
  • StrongBuy: 6
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ABCL price?
Analysts Target Price 9.2 160.5%
Abcellera Biologics (ABCL) - Fundamental Data Overview as of 05 April 2026
P/E Forward = 27.5482
P/S = 14.2041
P/B = 1.1021
Revenue TTM = 75.1m USD
EBIT TTM = -197.4m USD
EBITDA TTM = -175.3m USD
Long Term Debt = 143.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.82m USD (from shortTermDebt, last quarter)
Debt = 143.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -11.8m USD (from netDebt column, last quarter)
Enterprise Value = 650.0m USD (1.07b + Debt 143.2m - CCE 560.3m)
Interest Coverage Ratio = -8.17 (Ebit TTM -197.4m / Interest Expense TTM 24.2m)
EV/FCF = -3.73x (Enterprise Value 650.0m / FCF TTM -174.1m)
FCF Yield = -26.78% (FCF TTM -174.1m / Enterprise Value 650.0m)
 FCF Margin = -231.7% (FCF TTM -174.1m / Revenue TTM 75.1m)
 Net Margin = -194.9% (Net Income TTM -146.4m / Revenue TTM 75.1m)
Gross Margin = -10.41% ((Revenue TTM 75.1m - Cost of Revenue TTM 83.0m) / Revenue TTM)
Gross Margin QoQ = 25.54% (prev none%)
Tobins Q-Ratio = 0.48 (Enterprise Value 650.0m / Total Assets 1.36b)
Interest Expense / Debt = 11.24% (Interest Expense 16.1m / Debt 143.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -156.0m (EBIT -197.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.32 (Total Current Assets 728.2m / Total Current Liabilities 64.3m)
Debt / Equity = 0.13 (Debt 143.2m / totalStockholderEquity, last quarter 1.14b)
 Debt / EBITDA = 0.07 (negative EBITDA) (Net Debt -11.8m / EBITDA -175.3m)
 Debt / FCF = 0.07 (negative FCF - burning cash) (Net Debt -11.8m / FCF TTM -174.1m)
 Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.78% (Net Income -146.4m / Total Assets 1.36b)
RoE = -14.16% (Net Income TTM -146.4m / Total Stockholder Equity 1.03b)
RoCE = -16.77% (EBIT -197.4m / Capital Employed (Equity 1.03b + L.T.Debt 143.2m))
 RoIC = -15.75% (negative operating profit) (NOPAT -156.0m / Invested Capital 990.2m)
 WACC = 12.37% (E(1.07b)/V(1.21b) * Re(12.84%) + D(143.2m)/V(1.21b) * Rd(11.24%) * (1-Tc(0.21)))
Discount Rate = 12.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.72%
 [DCF] Fair Price = unknown (Cash Flow -174.1m)
 EPS Correlation: -22.24 | EPS CAGR: 2.82% | SUE: 2.70 | # QB: 2
Revenue Correlation: -53.61 | Revenue CAGR: -40.61% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-0.20 | Chg7d=-0.040 | Chg30d=-0.025 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.70 | Chg7d=-0.062 | Chg30d=-0.007 | Revisions Net=+0 | Growth EPS=-42.2% | Growth Revenue=-60.2%
EPS next Year (2027-12-31): EPS=-0.77 | Chg7d=-0.405 | Chg30d=-0.283 | Revisions Net=-1 | Growth EPS=-10.5% | Growth Revenue=+20.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle